20 completed. 20 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 20 |
Follow Healthy Subject: new trials by email Literature Review of Healthy Subject trials Research Report on Healthy Subject
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects YHP2406, YHR2501 - Healthy Subject | Phase 1 | Completed | Yuhan Corporation | 64 | 2025-06-29 | 2025-07-24 |
| To Evaluate the Safety and Tolerability of Multiple Doses of GS3-007a Oral Solution in Healthy Subjects. GS3-007 oral liquid - Healthy Subject | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 36 | 2023-06-19 | 2023-11-09 |
| A Study of STSA-1002 in Healthy Subjects STSA-1002 Injection, Placebo - Healthy Subject | Phase 1 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 26 | 2022-10-14 | 2023-04-18 |
| GS3-007a Oral Solution in Healthy Subjects GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication - Healthy Subject | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 96 | 2022-09-22 | 2023-04-11 |
| An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers Ursodeoxycholic Acid 250 Mg Oral Tablet - Healthy Subject | Phase 1 | Completed | Daewoong Pharmaceutical Co. LTD. | 44 | 2022-01-27 | 2023-04-27 |
| A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers SACT-1, EDURANT 25Mg Tablet - Healthy Subject | Phase 1 | Completed | Aptorum International Limited | 16 | 2021-10-09 | 2022-05-26 |
| Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects CT-P41, US-licensed Prolia - Healthy Subject | Phase 1 | Completed | Celltrion | 154 | 2021-10-06 | 2023-09-14 |
| Phase 1 Study of 3D229 in Healthy Subjects 3D229, Placebo - Healthy Subject | Phase 1 | Completed | 3D Medicines | 24 | 2021-07-27 | 2022-06-22 |
| A Study of ALS-4 in Healthy Adults Subjects ALS-4, Placebo - Healthy Subject | Phase 1 | Completed | Aptorum International Limited | 72 | 2021-03-20 | 2022-04-25 |
| A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults Bardoxolone methyl - Healthy Subject | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 36 | 2019-04-04 | 2020-02-05 |
| A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects Saline, ACT-246475, Rifampicin - Healthy Subject | Phase 1 | Completed | Viatris Innovation GmbH | 14 | 2019-01-03 | 2025-07-03 |
| Bioequivalence Study in Healthy Subjects by Using of Chlorpromazine HCl 100mg Tablets Chlorpromazine HCl 100mg Tablets - Healthy Subject | Phase 1 | Completed | Whanin Pharmaceutical Company | 70 | 2018-12-06 | 2023-12-08 |
| Evaluate Safety, Tolerability and Pharmacokinetics of Fadanafil （XZP-5849）in Chinese Healthy Adult Male Subjects Fadanafil, Placebo - Healthy Subject | Phase 1 | Completed | Sihuan Pharmaceutical Holdings Group Ltd. | 66 | 2018-08-10 | 2020-03-18 |
| Glucosamine and Chondroitin in Gut in Preventing People From Inflammation Glucosamine Sulfate/Chondroitin Sulfate Tablet, Placebo - Healthy Subject | Phase 1 | Completed | Fred Hutchinson Cancer Center | 9 | 2018-05-11 | 2019-05-24 |
| Glucosamine and Chondroitin in Preventing Inflammation in Overweight Patients Glucosamine, Placebo - Healthy Subject, Overweight | Phase 1 | Completed | Fred Hutchinson Cancer Center | 2 | 2017-08-01 | 2019-02-01 |
| Human Mass Balance Study of HMS5552 in Healthy Subjects HMS5552 - Healthy Subject | Phase 1 | Completed | Hua Medicine Limited | 6 | 2017-03-29 | 2018-12-31 |
| A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects Cohort 1: HL217 Ophathalmic Solution QD, Cohort 2: HL217 Ophathalmic Solution BID, Cohort 3: HL217 Ophthalmic Solution QID - Healthy Subject | Phase 1 | Completed | Hanlim Pharm. Co., Ltd. | 24 | 2016-08-01 | 2019-04-01 |
| Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem inClinical Healthy Subjects Banapenem - Healthy Subject | Phase 1 | Completed | Sihuan Pharmaceutical Holdings Group Ltd. | 36 | 2016-03-14 | 2018-06-27 |
| Single-dose PK Study of Benapenem In Healthy Subjects Benapenem, Placebo - Healthy Subject | Phase 1 | Completed | Sihuan Pharmaceutical Holdings Group Ltd. | 98 | 2015-03-11 | 2018-07-17 |
| Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers Laboratory Biomarker Analysis, Pharmacological Study, Placebo - Healthy Subject | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2013-08-01 | 2016-12-23 |
Overweight (1)
Body Weight (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Glucosamine (2) · Tablets (2) · 1,2-dibenzoyl-tert-butylhydrazine (1) · Chlorpromazine (1) · Chondroitin Sulfates (1) · Dorzagliatin (1) · Rifampin (1) · Rilpivirine (1) · Sodium Chloride (1) · UAB 30 (1) · Ursodeoxycholic Acid (1) · bardoxolone methyl (1) · benapenem (1) · selatogrel (1)
Sihuan Pharmaceutical Holdings Group Ltd. (3) · Aptorum International Limited (2) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · Fred Hutchinson Cancer Center (2) · 3D Medicines (1) · Celltrion (1) · Daewoong Pharmaceutical Co. LTD. (1) · Hanlim Pharm. Co., Ltd. (1) · Hua Medicine Limited (1) · Kyowa Kirin Co., Ltd. (1) · National Cancer Institute (NCI) (1) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (1) · Viatris Innovation GmbH (1) · Whanin Pharmaceutical Company (1) · Yuhan Corporation (1)
China (5) · United States (5) · South Korea (4) · Canada (1) · Japan (1) · Netherlands (1)
Thomas Lee, PhD (2) · Charles Tomek, MD (1) · David Bell (1) · Haiyan Li, Doctor (1) · Jill Kolesar (1) · Joanna Lampe (1) · Johanna Lampe (1) · Seoung Hyun Kang (1) · Xinghe Wang, Ph.D (1) · Yan Zhu, Doctor (1) · Yuan Lv, PhD (1)
PMID 30617093, PMID 32166864, PMID 38349618, PMID 42394970
2018 (1), N01CN35153 (1), P30CA014520 (1)